Telmisartan: a review of its use in hypertension
- PMID: 11558835
- DOI: 10.2165/00003495-200161100-00009
Telmisartan: a review of its use in hypertension
Abstract
Telmisartan is an angiotensin II receptor antagonist that is highly selective for type 1 angiotensin II receptors. It was significantly more effective than placebo in large (n >100), double-blind, randomised, multicentre clinical trials in patients with mild to moderate hypertension. Telmisartan 20 to 160 mg once daily produced mean reductions in supine trough systolic blood pressure and diastolic blood pressure of up to 15.5 and 10.5 mm Hg, respectively. Maximum blood pressure reduction occurred with a dosage of 40 to 80 mg/day. Telmisartan 40 to 120 mg/day was as effective as amlodipine 5 to 10 mg/day or atenolol 50 to 100 mg/day in dose-titration studies. Telmisartan 20 to 160 mg/day was generally similar in efficacy to enalapril 5 to 20 mg/day or lisinopril 10 to 40 mg/day in both titration-to-response and other studies. Hydrochlorothiazide was coadministered in most of the titration-to-response studies if patients remained hypertensive. Telmisartan 80 mg/day was more effective than submaximal dosages of losartan (50 mg/day) or valsartan (80 mg/day) and was as effective as a fixed-dose combination of losartan 50 mg plus hydrochlorothiazide 12.5 mg over the last 6 hours of the dosage interval and the whole 24-hour postdose interval. In patients with severe hypertension, telmisartan 80 to 160 mg/day was as effective as enalapril 20 to 40 mg/day (both agents could be titrated and combined sequentially with hydrochlorothiazide 25 mg and amlodipine 5 mg). The addition of hydrochlorothiazide to telmisartan was more effective than each agent alone at lowering blood pressure in patients with hypertension. Telmisartan was well tolerated in patients with mild to moderate hypertension and was significantly less likely to cause persistent, dry cough than lisinopril.
Conclusion: Telmisartan is an effective antihypertensive agent with a tolerability profile similar to that of placebo. Comparative data have shown telmisartan to be as effective as other major classes of antihypertensive agents at lowering blood pressure. Compared with lisinopril, telmisartan is associated with a significantly lower incidence of dry, persistent cough. Therefore, telmisartan is a useful therapeutic option in the management of patients with hypertension.
Similar articles
-
Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. TEES Study Group.J Hypertens. 1999 Feb;17(2):293-302. doi: 10.1097/00004872-199917020-00015. J Hypertens. 1999. PMID: 10067800 Clinical Trial.
-
Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension.Am J Ther. 1999 May;6(3):161-6. doi: 10.1097/00045391-199905000-00007. Am J Ther. 1999. PMID: 10423659 Clinical Trial.
-
Telmisartan/hydrochlorothiazide: in the treatment of essential hypertension.Drugs. 2003;63(19):2013-26; discussion 2027-8. doi: 10.2165/00003495-200363190-00006. Drugs. 2003. PMID: 12962518 Review.
-
Dose response and safety of telmisartan in patients with mild to moderate hypertension.J Clin Pharmacol. 2000 Dec;40(12 Pt 1):1380-90. J Clin Pharmacol. 2000. PMID: 11185637 Clinical Trial.
-
Telmisartan.Drugs. 1998 Dec;56(6):1039-44; discussion 1045-6. doi: 10.2165/00003495-199856060-00007. Drugs. 1998. PMID: 9878991 Review.
Cited by
-
Effects of telmisartan on office and 24-hour ambulatory blood pressure: an observational study in hypertensive patients managed in primary care.Vasc Health Risk Manag. 2010 Feb 4;6:31-8. doi: 10.2147/vhrm.s9122. Vasc Health Risk Manag. 2010. PMID: 20191081 Free PMC article.
-
Telmisartan: a review of its use in cardiovascular disease prevention.Drugs. 2011 Apr 16;71(6):651-77. doi: 10.2165/11206710-000000000-00000. Drugs. 2011. PMID: 21504246 Review.
-
Treatment of proteinuria in dogs with telmisartan: A retrospective study.J Vet Intern Med. 2021 Jul;35(4):1810-1818. doi: 10.1111/jvim.16146. Epub 2021 May 10. J Vet Intern Med. 2021. PMID: 33969924 Free PMC article.
-
Efficacy and Safety of Triple Therapy of Telmisartan/Amlodipine/Rosuvastatin in Patients with Dyslipidemia and Hypertension: A Multicenter Randomized Clinical Trial.Curr Ther Res Clin Exp. 2024 Feb 1;100:100735. doi: 10.1016/j.curtheres.2024.100735. eCollection 2024. Curr Ther Res Clin Exp. 2024. PMID: 38380420 Free PMC article.
-
Safety of telmisartan in patients with arterial hypertension : an open-label observational study.Drug Saf. 2004;27(5):335-44. doi: 10.2165/00002018-200427050-00005. Drug Saf. 2004. PMID: 15061687 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical